One contribution of 9 to a theme issue 'The virtual physiological human: translating the VPH to the clinic'. Routine treatment of mild to moderate pain with a combination of non-steroidal anti-inflammatory drugs such as paracetamol in combination with corticoid opioids can lead to severe complications including death from gastrointestinal injury or to drug dependence. There is a need for the development of new safer drugs. Chemerin is a mediator promoting resolution of inflammation and it is then a promising candidate for a new treatment. A pilot experimental work using the zymosan-induced peritonitis model has found that injecting extra chemerin resulted in an approximately 1% reduction in the total number of inflammatory cells recruited. This paper combines and adapts existing mathematical models of inflammation to reproduce these results and to explore the therapeutic potential of chemerin through simulations. Analysis of the model predicts that the injection of chemerin at a concentration of 2000 ng ml 21 within the first 5 min of inflammation onset leads to maximal inflammation inhibition. The degree of inhibition is shown to be sensitive to data used for the fit with a mean inhibition of 22 + 3.7% for a series of remove-one bootstrap tests, whereas optimal chemerin injection parameters were not. Overall sensitivity analysis identifies parameters of the model that need to be measured more accurately or with increased sampling rate to improve model robustness and confirm chemerin's therapeutic potential.
Introduction
Chronic pain, a key feature of inflammation, is a leading cause of morbidity worldwide with an estimated prevalence as high as 50% in Europe [1] . Based on a survey of over 46 000 respondents, chronic pain is reported to affect 19% of Europeans [2] . Seven out of 28 prevalence studies included in a recent report on pain in the EU showed a strong link between chronic pain and ageing [3] . Hence, the prevalence of pain is expected to increase in ageing populations.
Typical treatment of mild to moderate pain involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as paracetamol [1] . However, the use of NSAIDs may lead to complications including gastrointestinal (GI) symptoms (especially for patients with a high cardiovascular risk) which can result in fatal peptic ulceration and bleeding-about 2500 people die in the UK each year due to NSAID-related GI [4] . Hence, there is a need for new and safe drugs.
To achieve this goal, there has been interest in characterizing the role of mediators in the successful termination of the inflammatory response. In particular, the role of resolvins and chemerin-derived peptides, which mediate their effects through the ChemR23 G protein-coupled receptors, has been examined [5] .
To test the inhibitory effect potential of chemerin, an experimental pilot study was performed with a zymosan-induced peritonitis mouse model of inflammation [6] (detailed in the Material and methods section). The study showed that recruitment of inflammatory cells is indeed reduced when & 2018 The Author(s) Published by the Royal Society. All rights reserved.
chemerin with a concentration of 500 mg ml 21 is injected in the peritoneum 2 h after inflammation onset. There is a need now to characterize both the drug concentration and timing of injection that optimize inflammation inhibition to evaluate chemerin's therapeutic potential. As assessing the time course of just one treatment approach requires the sacrifice of approximately 50 mice for statistical significance, it would be time-consuming and ethically questionable to do an exhaustive experimental search for the optimum. Hence, we introduce a mathematical model of zymosan-induced peritonitis and its modulation by chemerin to identify chemerin delivery optimization hypotheses for further experimental validation. This modelling study constitutes a step towards developing generic methods for following inflammation kinetics in pre-clinical models prior to any translational studies in human volunteers.
Material and methods

Measurement of chemerin inhibition using a zymosan-induced peritonitis model
For acquiring pilot data, the experimental procedure described by Cash et al. [6] has been used. The method consists of inducing peritonitis by injecting zymosan into a mouse peritoneum. At regular intervals from onset, the animals are sacrificed by exposing them to increasing concentrations of CO 2 and with death confirmed with cervical dislocation. The peritoneum of the sacrificed mice is lavaged to count inflammatory cells and measure the concentration of inflammatory mediators. Cash et al. [6] have shown that this procedure has several advantages compared to other models of inflammation: (i) it enables modulation of the severity of the inflammatory insult dependent on the concentration of zymosan injected; (ii) it allows for the collection of a reasonable quantity of exudate for the analysis of multiple inflammatory mediators; (iii) compared to artificial cavities, the peritoneum provides a more realistic experimental environment as it has lymphatic clearance of inflammatory cells and (iv) it is a simple reproducible procedure.
This procedure was used to measure the concentration of inflammatory chemokines such as CXCL1, CCL2 and chemerin as well as the number of neutrophils and monocytes. The steps consisted of inducing peritonitis and killing a variable number of animals at intervals up to 96 h after onset.
To evaluate the inhibitory effect of chemerin, the procedure was modified by injecting 500 mg ml 21 of chemerin 2 h after inflammation was induced. At 4 and 16 h post-onset, the animals were sacrificed and the number of inflammatory cells was measured. Through this procedure, it was found that the number of neutrophils and monocytes is reduced by up to 7% 2 h after onset. At 16 h, the numbers are reduced by 12% and 20% for neutrophils and monocytes, respectively. Therefore, a significant inhibitory effect was identified. The remainder of the paper details the design of a mathematical model of the progress of inflammation in the zymosan mouse model to identify likely optimal chemerin injection parameters and hence reduce the extent of experimental work required to find this result. All collected data are provided in the electronic supplementary material.
Overview of the mechanisms of acute inflammation modulation by chemerin
Chemerin is a plasmacytoid dendritic cell, a natural killer cell and a macrophage chemoattractant naturally found in the circulation [7] . Chemerin is present in the circulation and is secreted as an inactive precursor. It needs to undergo C-terminal proteolytic cleavage by neutrophil proteases to become active ( figure 1a ). An increased concentration of neutrophils, aimed at killing infectious agents, is characteristic for inflamed tissue and hence chemerin becomes active as inflammation develops. Activated chemerin becomes a monocyte chemoattractant. Diffusing through the tissue and into blood vessels, it binds to ChemR23 receptors of monocytes and recruits them, from the circulation into the tissue and towards the inflammation site, where their role is to clear apoptotic neutrophils and inflammation by-products (figure 1b,c). At the site of inflammation, macrophages produced from monocytes release proteases (figure 1d ), which break down chemerin into peptides (figure 1e). In particular, the resulting peptide C15 binds to Figure 1 . Schematic representation of the key seven stages of the modulation of inflammation by chemerin [7] . (a) Neutrophils are recruited to the inflammation site and secrete pro-chemerin proteases. (b,c) Proteases activate chemerin precursors. The activated chemerin is a chemoattractant for monocytes, which are recruited to the inflammation site from blood vessels and are transported through chemotaxis. (d ) Once at the inflammation site, monocytes differentiate into macrophages, which clear apoptotic neutrophils and inflammation debris. This activity leads to the release of macrophage proteases which breakdown chemerin into peptides, including the C15 peptide. (e) The C15 peptide binds to the macrophages, which (f ) inhibits their release of pro-inflammatory cytokines and chemokines and (g) promotes phagocytosis of apoptotic neutrophils.
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the receptor ChemR23 of macrophages, which has proresolving effects, i.e. it inhibits the release of pro-inflammatory chemokines (figure 1f ) and it promotes apoptotic neutrophil phagocytosis (figure 1g). The full Chem/ChemR23 system is summarized in figure 1 [7] . Therefore, the key characteristic affecting the resolution of the inflammatory response that needs to be modelled is the competing action of pro-and anti-inflammatory mediators that affect the recruitment of neutrophils and monocytes after their sequential arrival to the inflammatory site.
Mathematical models of acute inflammation
Several mathematical models of acute inflammatory response were developed. Lauffenburger & Kennedy [8, 9] characterized leucocyte recruitment to a bacterial infection site. The role of cytokines and anti-inflammatory mediators was later characterized by Rudnev & Romanyukha [10] and Reynolds et al. [11] , respectively.
The recruitment and function of different populations of inflammatory cells is, however, only found in the work by Dunster et al. [12] and Smith et al. [13] . Additionally, the work by Smith et al. [13] is the only work that models the sequential arrival of neutrophils followed by monocytes. Furthermore, the work by Dunster et al. [12] equates pro-inflammatory and anti-inflammatory mechanisms.
The model proposed here aims at predicting the generic inflammatory response in the presence of an intervention. It consists of the combination of the relevant mechanisms from other inflammatory response models, as detailed above, and the further inclusion of the pro-and anti-inflammatory effects of chemerin based on the work by Cash et al. [7] . The model is described in the sections below.
Model of the modulation of zymosan-induced peritonitis by chemerin
The combined and adapted model is composed of eight variables including: the inflamogen zymosan (Z ), the number of neutrophils (N), the number of apoptotic neutrophils (A), the number of monocytes (M), cytokines CCL2 (C 2 ) and CXCL1 (C 1 ), chemerin (C h ) and anti-inflammatory mediators (G). The model is summarized in figure 2 . Parts of the model are explained in the following subsections.
Pro-and anti-inflammatory chemokine production
Attractants for inflammatory cells expressed in the zymosan peritonitis model include IL-6, CCL4, CXCL10, CXCL1 and CCL2. Here, only CXCL1 and CCL2 chemokines have been considered as they are the main chemokines for the recruitment of neutrophils and monocytes, respectively [14] . Following Smith et al.
[13], the recruitment of the neutrophils and monocytes is sequential. However, the authors assumed a constant delay between the arrival of the two species, which would not be appropriate here, as the model is intended to capture the injection of chemerin at different times during inflammation. Instead, neutrophil and monocyte-specific chemokines were defined.
As neutrophils are first recruited cells, it was assumed that the tissue cells produce C 1 as zymosan is injected. Additionally, the data show that chemerin starts being produced by the tissue rsfs.royalsocietypublishing.org Interface Focus 8: 20170007
as soon as zymosan is injected. Therefore, chemerin production was assumed to be triggered by the injection of zymosan. The mechanisms responsible for the production of cytokines involve enzymatic reactions [12] . Therefore, the production of C 1 and C h in response to Z is assumed to have the Michaelis -Menten kinetics as:
where m Z stands for C 1 or C h and k m Z and V m Z are the MichaelisMenten parameters related to each chemokine. At the inflammation site, the neutrophils that are not cleared by the circulation become apoptotic. As described in Smith et al.
[13], the rate of apoptosis, k an , is proportional to the number of neutrophils as:
ð2:2Þ
Both neutrophils and apoptotic neutrophils contribute to the promotion of inflammation by stimulating the production of CXCL1. Additionally, neutrophils intervene in mechanisms that result in the recruitment of monocytes [15] . It is assumed that all those mechanisms can be captured by making the production of CCL2 and chemerin dependent on N and A. Neutrophil production of chemokines was modelled based on the work by Dunster et al. [12] as:
where I stands for either N or A, m for the type of cytokine produced (C 1 , C 2 or C h ), k I,m is a parameter specific to each cytokine and cell pair and w I,m is the order of the chemokine function rate.
Neutrophil and monocyte chemotaxis
Neutrophil and monocyte chemotaxis was modelled based on the work by Smith et al. [13] . Neutrophils are recruited at a rate, k c1n , proportional to CXCL1 concentration. Additionally, according to Smith et al.
[13], a maximum number of neutrophils, N max , is set to account for the saturation of space available for these cells as inflammation progresses. The resulting flow of neutrophils is represented by
ð2:4Þ
Similarly, monocyte chemotaxis is modelled by setting the rate of recruitment to be proportional to chemerin and CCL2 concentrations and imposing a maximum number of monocytes, M max , to account for the saturation of space as inflammation progresses. Hence, monocyte recruitment is modelled as
where k cm and k hm are the rate constants for monocyte recruitment due to CCL2 and chemerin, respectively.
Zymosan and apoptotic neutrophil phagocytosis
Following the work of Dunster et al. [12] , the phagocytosis rate of zymosan is performed by both neutrophils and monocytes at rates k pn and k pm proportional to their number, respectively
The apoptotic neutrophils are phagocytosed by monocytes as in Dunster et al. [12] at a rate k pa as:
ð2:7Þ
Anti-inflammatory chemokine production and role in neutrophil recruitment and phagocytosis action
Two anti-inflammatory cytokines are considered: a generic chemokine G, as in Durnster et al. [12] , and the chemerin peptide C 15 . The former is produced proportionally (k g ) to the phagocytosis of apoptotic neutrophils by monocytes as:
ð2:8Þ C 15 is formed by the breakdown of chemerin by macrophage proteases (figure 1d). As it is an enzymatic reaction, it is modelled with the Michaelis -Menten kinetics with parameters V C15 and K m,C15 as:
Following Durnster et al. [12] , the anti-inflammatory chemokines inhibit neutrophil recruitment. Here, the recruitment of neutrophils is performed by CXCL1. It was then assumed that the anti-inflammatory chemokines inhibit the production of CXCL1. This was done by modifying equations (2.1) and (2.3) following Anderson et al. [16] leading to
and
where I stands for N and A and k Z,C15 , k I,C15 , w Z,C15 , w I,C15 and k Z,G , k I,G , w Z,G , w I,G are the parameters for C 15 and G inhibition, respectively. Additionally, C 15 promotes phagocytosis [17] . To account for this promotion, the rate of phagocytosis defined in equation (2.7) was adapted by including C 15 dependence based on the chemokine promotion model by Dunster et al. [12] leading to:
ð2:12Þ
Injection of additional chemerin model
The rate of injection of extra chemerin [C h ] i was modelled as the derivative of a step function as:
where d and t are the parameters that define the speed of the step function and the time when the step occurs, respectively. t was chosen to match the experimental procedure performed where extra chemerin is injected 2 h after inflammation is induced. The remaining parameter d was defined by trying to ensure that it would make the step function as fast as possible and to ensure solution stability. Taking these two aspects into consideration, the maximum speed for the injection was found to be 10 min. This is unrealistic as an injection is on the timescale of a few seconds. However, as the experiments take up to 96 h, it is here assumed that the difference between the injection taking seconds or a few minutes is negligible.
Clearance model
The rate of clearance of free inflammatory agents by the vasculature is assumed to be proportional to their concentration as 
Implementations
The model was developed using Matlab (v. R2016a, Mathworks, MA, USA). The IQM SBML package (v. V.2.1, Basel, Switzerland) developed by Schmidt & Jirstand [18] was used for fitting the model. Additionally, the optimization algorithms provided by the IQM package were used for identifying the optimal injection of chemerin to inhibit recruitment of inflammatory cells. The model simulations were performed using the Matlab provided solver 'ode23s' catered for stiff ODE systems. The solver was used with default Matlab settings. Sensitivity analysis was carried using the Compolongo -Morris method. The method was implemented based on the work by Saltelli et al. [19] .
Data for model fitting
The procedure described by Cash et al. [6] was used to obtain the data used to fit the model. The animal experiment consists of inducing inflammation by injecting 100 mg ml 21 of zymosan into the mouse peritonitis cavity. About 500 mg ml 21 of recombinant murine chemerin (R&D systems; aa17 -156) were injected 2 h later. At different times up to 96 h after zymosan injection, the animals were sacrificed. For each animal, the number of neutrophils, monocytes and the concentration of chemokines CCL2, CXL1 and chemerin in the peritoneum cavity was measured. For each data point, 5 -10 animals were sacrificed.
Results
Model fitting
Wherever possible, model parameters were defined based on values reported in the literature or directly available from the data. Malech [20] reported the rate constant of neutrophil clearance ðg N Þ. The clearance rate of all cytokines (g C1 , g C2, g H and g C15 ) was set to the measured generic value [21] . All set parameters are summarized in table 2. Experimentally, it was possible to define the saturation levels N max and M max as 4 Â 10 6 and 9 Â 10 6 cells, respectively, based on the measurements performed when 500 mg ml 21 of zymosan is injected into the peritoneum. The remaining parameters were fitted numerically. The allowed range for all fitted parameters was set empirically, so that to reflect the rate at which different variables evolve during the experimental study. Two sets of data were used for the fitting: The model has 47 parameters with a wide parameter space and needs to be fitted to 40 data points spanning five variables of which two are measured in two experiments. For this reason, because it is hard to envisage how the fit varies as the parameter space is sampled, methods designed to avoid local minima were considered to perform the fit.
The initial selection of the fitting method was performed by running all global optimization methods from the SBML toolbox, the method that produced the best fit in a reasonable time was the simplex method [22] . The result of the fit is shown in figure 3 and the full list of fitted parameters is provided in table 3. Table 1 . Summary of the conservation of mass equations of the chemerin inflammation modulation model.
Fitting errors were normalized with respect to the maximum value measured for each variable to ensure equal weighting of each one in the final fit. This was achieved by setting the root mean square (RMS) value to
where S x is the simulated value, D x the data point, the index x stands for the different variables being fitted and max(D x ) stands for the maximum of the dataset. As shown in figure 3 , the fit exhibits all key characteristics observed in measurements: the sequential arrival of neutrophils and monocytes (figure 3c); the removal of neutrophils and monocytes from the inflammatory site (figure 3c); as well as sharp peaks of numbers and concentrations of inflammatory cells and chemokines, respectively. Achieved RMS values are predominantly low and approximately 0.05, 0.1, 0.09 and 0.12 for neutrophils, monocytes, chemerin and CXCL1, respectively. The RMS value for CCL2 is 0.47 and is due to a rapidly varying function where a small time delay between the fitted and measured curves leads to a large RMS error.
RMS values for chemerin injection experiments were also low with 0.01 and 0.03 for neutrophils and monocytes, respectively.
Optimizing the therapeutic potential of chemerin
The aim of this work is to identify the optimal concentration and time of injection of chemerin to inhibit inflammation. These two parameters, [C h ] i and t, respectively, are the inputs to equation (2.13). The extent of the inhibitory effect W of chemerin is evaluated by comparing the average number of all inflammatory cells over the course of the experiment, i.e. 96 h, with and without chemerin injected. This can be expressed as injecting chemerin was as soon as possible after inflammation onset. Hence, to simulate immediate chemerin injection, the initial concentration of chemerin was set to of chemerin is injected. The maximum inhibitory effect is reduced by 1% when the injection is delayed by 5 min. After the maximum inhibitory effect is reached, injection of further chemerin will increase the total number of cells. This effect can be explained by the dual role that chemerin exhibits in the inflammatory pathway. On the one hand, it attracts monocytes and on the other hand, it leads to further production of C15 that inhibits neutrophil recruitment and promotes apoptotic neutrophil phagocytosis. The maximum inhibition found is more than double the effect observed in the pilot experimental study.
When breaking down the 27% reduction in the total of inflammatory cells into the three types of inflammatory cells considered, there was an inhibition of approximately 53% and 6% in the number of monocytes and neutrophils, respectively. However, there was an increase in apoptotic neutrophils by approximately 160%.
As apoptotic neutrophils have been found to play a crucial role in the degeneration of acute inflammation into chronic inflammation [11] , a second set of optimizing tests was undertaken to identify the optimal conditions for injecting chemerin to reduce the number of neutrophils and apoptotic neutrophils (x ¼ N, A). As in the case of total cell inhibition optimization, the maximum inhibition of neutrophils for injections of increasing chemerin concentration occurs when chemerin is injected simultaneously with the trigger for inflammation. Furthermore, as seen in figure 4b, a maximum inhibition was found of approximately 35% and 88% in neutrophils and apoptotic neutrophils, respectively. However, as chemerin concentration increases so does the number of monocytes by approximately 74%.
Sensitivity analysis
To assess the risk of overfitting, a screening algorithm was performed on the fitted model. The model consists of eight ODE equations (equations (2.15) -(2.23)) with 47 parameters. Owing to its large size and the number of parameters, it was decided to use a global rather than local method. As it is anticipated that this complex model will not be stable over .1)) resulting in a 35% reduction in neutrophils, a 88% reduction in apoptotic neutrophils and an increase in monocyte recruitment of 70% when greater than or equal to 1 Â 10 5 ng ml 21 of chemerin is injected. the whole parameter space, the global Compolongo -Morris (C-M) method was chosen. Furthermore, to assess the risk of sensitivity to data, a remove-one bootstrap [23] analysis was performed. Both studies are reported below.
Compolongo-Morris screening analysis
This algorithm consists of exploring the parameter space by varying each parameter from of model (including the parameters in tables 2 and 3 and the data-derived parameters N max and M max ) in turn over a pre-defined range [19] . As the range found for parameter definitions in the literature, as in Smith et al. [13] , is large, the range was chosen to be +80% of the value fitted.
Each time a parameter is varied, its impact on the output of the model is evaluated, which is termed elementary effect (EE). This analysis aims at identifying which parameters impact the model fit and the model predictions of cell recruitment inhibition by injecting extra chemerin; therefore, the EEs were defined as the sum between: (i) the RMS between the model with the new parameter definitions and the data using equation (3.1) and (ii) the RMS between the fitted model simulations when extra chemerin is injected and the model with the new parameter values, again using equation (3.1). Inclusion of this sum ensures that the analysis takes into consideration the behaviour of the model with and without extra chemerin injected.
The analysis is run over a series of EE calculations. From all the EEs, standard deviation (s) and absolute mean (m Ã ) are calculated for each parameter. The advantage of computing the absolute mean is that it captures the cumulative effect of varying each parameter in contrast with the mean, which would be affected by the signs of EEs. In figure 5 , the results are plotted for all the parameters. A large value of m Ã establishes that the parameter has a large effect on the output, while those with a small value are unimportant. Additionally, the value of s can be used to distinguish between those parameters that have a linear independent effect (small s) and those with a nonlinear effect (large s).
EE statistics are plotted in figure 5 . Figure 5b shows that the model is most sensitive to the parameters pertaining to the production and removal of the chemokines CXCL1 and CCL2. Additionally, the rate of apoptotic neutrophils by monocytes (k pa ) has a marked impact on the behaviour of the model. The data-derived parameters that describe the maximum number of neutrophils (N max ) and monocytes (M max ) have also been found to impact the fit and the models predictions. Related to cellular number kinetics, the rate of monocyte extraction rate (g m ) was also found to substantially impact model behaviour.
To quantify how the most sensitive parameters (figure 5b) impact model predictions in more detail, the CompolongoMorris method was reapplied. The remaining parameters of the model were kept constant, while the sensitive parameters were varied by +5%. EEs were redefined to assess the change in predicted maximum inhibition, optimal time of injection and optimal chemerin concentration as in equation (3.1). It was found that the optimal concentration was constant for all simulations, the percentage of total cell inhibition was found to vary between 20% and 34% and the maximum neutrophil inhibitory effect varied between 30% and 40%. Figure 5a presents the parameters found to perturb the summed RMS by less than 1%. These parameters are related to the production of cytokines by apoptotic neutrophils and to the inhibitory effect of the generic pro-resolving cytokine (G). As the parameters presented in figure 5a ( 
, w A,C2 ) have negligible effect on the output of the model, they were removed. Starting with the parameters V A,C h and k A,C h , their removal leads to Similarly for apoptotic neutrophils, the parameters V A,C1 , k A,C1 , , w A,G and k A,G were removed, leading to
ð3:5Þ
Simulations were performed to test the impact of removing the remaining parameters on the model fit and predictions. These simulations illustrate the limitations of the Compolongo-Morris which does not take into account the nonlinear relationship between parameters. From these simplifications, it was possible to reduce the free parameters from 47 down to 35 and an increase in summed RMS by less than 1 Â 10 23 %.
Remove-one bootstrap analysis
In the fitting process, seven variables tracked during the zymosan-induced peritonitis experiment were used. To check how the fit and key predictions are affected by measurements, one data point from each seven datasets before fitting was removed at random, i.e. it was possible to have up to seven data points removed at the same time for a simulation instance. The experiment was performed 100 times and changes in predicted optimal chemerin dosing and maximal expected inhibition were recorded. A histogram presenting the distribution of results was included in the electronic supplementary material. Inflammation inhibition varied between 10% and 35% (mean of 22% and standard deviation of 3.7%) of the control value (i.e. no chemerin injected). The optimal injection time and the optimal chemerin concentration did not change.
A further set of experiments was performed where only one data point at a time was removed per simulation instance. For measurements with a low standard derivation, the removal of a single data point did not affect inhibition significantly. In the case of high standard deviation measurements, i.e. in the dynamic range of the curves, presented inhibition varied between 10% and 60%.
Discussion
This work has led to the development of the first mathematical model of chemokine-mediated leucocyte recruitment and clearance during zymosan-induced peritonitis. As evidenced by results in §3.1, it was possible to fit the model to achieve rsfs.royalsocietypublishing.org Interface Focus 8: 20170007 good agreement with data from a pilot experimental study. RMS values were predominantly low; however, for more confidence in the quality of the fit, more data points should be acquired in the future to sample the studied functions with more frequency as they vary rapidly. Furthermore, individual point estimates in the dynamic range are based on measurements with a high standard deviation. More measurements per point or more precise timing for data collection will be necessary in the future to improve fit quality. Indeed, a remove-one bootstrap analysis showed that removing a single measurement from a signal point estimate in this dynamic range could lead to the inhibition changing by up to 25 percentage points (i.e. from 10% to 35% with mean 22% and standard deviation 3.7%).
Sensitivity analysis identified 12 out of 47 parameters that had little impact on the results of the model simulation. Furthermore, the analysis highlighted those parameters with high impact on the output of the model pointing to model assumptions that should be verified experimentally.
The fitted model was used to maximize theoretically the degree of inflammation inhibition by chemerin. In brief, a maximum inhibition of 27% of the average of total number of inflammatory cells over the course of the experiment was predicted for an immediate chemerin injection with concentration of about 2 Â 10 3 ng ml 21 . Optimization aimed at minimizing neutrophil recruitment found an optimal chemerin concentration of 10 5 ng ml 21 to be injected immediately after inflammation onset. These results are discussed in more detail below. Furthermore, individual point estimates in the dynamic range are based on measurements with a high standard deviation. More measurements per point or more precise timing for data collection will be necessary in the future to improve fit quality. Indeed, a remove-one bootstrap analysis showed that removing a single measurement from a signal point estimate in this dynamic range could lead to the inhibition changing by up to 50 percentage points (i.e. from 10% to 60%).
Sensitivity analysis
In the model here presented, production of CXCL1 depends on the zymosan concentration while the production of CCL2 depends on the number of neutrophils and apoptotic neutrophils attracted by CXCL1. Hence, the output of the model is sensitive to any variation of the rate of production of these chemokines as was correctly identified by sensitivity analysis. As the range set for these parameters during the fitting process was set somewhat arbitrarily, future experimental work is needed to confirm the values found and to provide more theoretical insight into the mechanisms behind the observed delay in recruitment of leucocytes.
The parameters that define apoptotic neutrophil phagocytosis (rate of monocyte phagocytosis and the rate of C15 promotion of phagocytosis) exert a noticeable effect on the output of the model. This is due to the assumption that the inflammatory process can only be resolved after total clearance of apoptotic neutrophils. In addition, the rate of circulatory monocyte clearance is also relevant for the behaviour of the model for the same reasons.
Conversely, the C-M method also identified the parameters that least affect the output. These are related to chemerin production by apoptotic neutrophils and to the inhibitory effect of G on chemokine production. In both cases, this lack of importance might be explained by a lack of data to inform the fitting.
The fitting process led to a solution where the number of apoptotic neutrophils is much lower than that of neutrophils (order of magnitude of 10 7 cells). Checking whether this is a realistic distribution should form part of future validation and development of the model. The model assumed that there is a generic chemokine G inhibiting neutrophil recruitment; further experimental work would be needed to identify prominent individual chemokines involved in this process.
Treatment perspectives involving chemerin/ ChemR23 pro-resolving pathway
Chemerin has been associated with a variety of conditions that have as one of its pathological mechanisms chronic inflammation. These include obesity, metabolic syndrome and diabetes [24] . Additionally, chemerin has been proposed as a biomarker for chronic inflammation, as its increased expression is found to be unique to the inflammatory region [25] . Assuming two therapeutic strategies consisting of either the reduction in the total number of inflammatory cells during the course of inflammation or focus on the reduction in the number of apoptotic neutrophils, the model predicted theoretical optimal solutions for both. In the first case, the model predicts that injecting chemerin up to 7 min after injecting zymosan at a concentration of 2 Â 10 3 ng ml 21 will have the maximum overall inhibitory effect of 27%. Individual cell recruitment in that case was reduced by 35% for monocytes and by 6% for neutrophils with a 160% increase in the number of apoptotic neutrophils. This result suggests that it is impossible to reduce the number of apoptotic neutrophils and monocytes simultaneously. This is a concern because, as suggested by Kumar et al. [14] , both types of cells are involved in the pathological mechanisms that lead to the degeneration of acute inflammation into chronic inflammation. This behaviour can be explained by the fact that the model assumes that inflammation can only be resolved if apoptotic neutrophils are cleared. Additionally, it is assumed that the mechanisms responsible for the clearance of these cells are diffusion of apoptotic cells into the circulation and monocyte phagocytosis. Therefore, a reduction in the number of monocytes will result in a larger presence of apoptotic neutrophils. Therefore, it should be investigated if there are other mechanisms of removal of apoptotic neutrophils. If a more dominant mechanism exists besides monocyte phagocytosis, perhaps there could be a strategy by which the injection of chemerin could reduce the number of monocytes and apoptotic neutrophils simultaneously.
In the second case, the model predicts that a large concentration of chemerin (1 Â 10 5 ng ml 21 ) needs to be injected up to 7 min after zymosan injection. Such a treatment would lead to approximately a 35% reduction in neutrophils as well as an 88% reduction in the number of apoptotic neutrophils. However, it also leads to a 70% increase in the number of monocytes. Above 1 Â 10 5 ng ml
21
, there is no increase in neutrophil inhibition and there is a linear increase in the number of monocytes.
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The inhibitory potential of chemerin identified by the model is informed by the efficiency of the fit. The model captures well the behaviour of variables in the control environment and when chemerin is injected until 16 h after peritonitis onset. Although there are data for longer periods of time in the control environment, there are no measurements when chemerin is injected. Consequently, when fitting the model to both types of datasets, the fitting algorithm assumes that the profile of neutrophil and monocyte behaviour resembles that of the control data. When computing the inhibitory effect of chemerin using equation (3.1), the full 96 h of simulation are used. Therefore, although the results show that chemerin is able to inhibit the number of cells recruited, it does not show if injecting chemerin aids in a faster resolution of inflammation. To overcome this limitation, it is proposed that using the zymosan-induced peritonitis procedure [6] , measurements of cellular species should be made at around 40 h after zymosan is injected. With the new data, it would be possible to confirm if the clearance of neutrophils and monocytes is faster in the presence of extra chemerin.
The results of this study contribute to the ongoing debate on whether chemerin has a generic anti-inflammatory function or whether it applies only to specific conditions [24] . Animal models have demonstrated a requirement of chemerin signalling in the development of inflammation and leucocyte infiltration [26] . Conversely, animal studies have shown that inhibition of endogenous chemerin activity exacerbates inflammation [24] . Additionally, the chemerin inhibitory pathway might require the involvement of other mediators, e.g. Resolvin E1, which shares some of the receptors to which chemerin attaches [27] .
Using the models referred to in this work, it was possible to capture the broad dynamics of the inhibitory role of chemerin during zymosan-induced peritonitis and to identify a high potential for inhibition with a specific selection of chemerin concentration and time of injection. These results encourage further experimental work to confirm simulation outcomes and allow for a detailed planning of future experimental work. The chemerin/ChemR23 pro-resolving pathway could be involved in many conditions and it is hoped that this model will serve as basis for the study of the role of chemerin in pathophysiology. 
